JP2016503070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503070A5 JP2016503070A5 JP2015551668A JP2015551668A JP2016503070A5 JP 2016503070 A5 JP2016503070 A5 JP 2016503070A5 JP 2015551668 A JP2015551668 A JP 2015551668A JP 2015551668 A JP2015551668 A JP 2015551668A JP 2016503070 A5 JP2016503070 A5 JP 2016503070A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- beta
- composition according
- beta cells
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 10
- 108009000020 Glucose Homeostasis Proteins 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 230000014101 glucose homeostasis Effects 0.000 claims 5
- 206010022114 Injury Diseases 0.000 claims 4
- 229960005486 vaccines Drugs 0.000 claims 4
- 230000001172 regenerating Effects 0.000 claims 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 229940119017 Cyclosporine Drugs 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 208000001280 Prediabetic State Diseases 0.000 claims 2
- 229940087463 Proleukin Drugs 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 230000001771 impaired Effects 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 230000003482 proton pump inhibitor Effects 0.000 claims 2
- 239000000612 proton pump inhibitor Substances 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
- 108010090726 Alefacept Proteins 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 102000008214 Glutamate decarboxylases Human genes 0.000 claims 1
- 108091022086 Glutamate decarboxylases Proteins 0.000 claims 1
- 210000002767 Hepatic Artery Anatomy 0.000 claims 1
- 101700082799 IL2RA Proteins 0.000 claims 1
- 102100002950 ISG20 Human genes 0.000 claims 1
- 101700015336 ISG20 Proteins 0.000 claims 1
- 206010022489 Insulin resistance Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108010023402 Interleukin 1 Receptor Antagonist Protein Proteins 0.000 claims 1
- 102000016664 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 210000004153 Islets of Langerhans Anatomy 0.000 claims 1
- 102100009073 LAD1 Human genes 0.000 claims 1
- 101700072115 LAD1 Proteins 0.000 claims 1
- 208000001921 Latent Autoimmune Diabetes in Adults Diseases 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 210000000496 Pancreas Anatomy 0.000 claims 1
- 210000003240 Portal Vein Anatomy 0.000 claims 1
- 208000008425 Protein Deficiency Diseases 0.000 claims 1
- 108010001645 Rituximab Proteins 0.000 claims 1
- 101710009148 SERPINA1 Proteins 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960001967 Tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 210000003606 Umbilical Veins Anatomy 0.000 claims 1
- 229940046008 Vitamin D Drugs 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- 229960002459 alefacept Drugs 0.000 claims 1
- 229960004238 anakinra Drugs 0.000 claims 1
- 230000001494 anti-thymocyte Effects 0.000 claims 1
- 230000001475 anti-trypsic Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 230000004153 glucose metabolism Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
- 210000004923 pancreatic tissues Anatomy 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 229920000333 poly(propyleneimine) Polymers 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 230000004936 stimulating Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000002753 trypsin inhibitor Substances 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361749197P | 2013-01-04 | 2013-01-04 | |
| US61/749,197 | 2013-01-04 | ||
| PCT/US2013/061972 WO2014052625A1 (en) | 2012-09-27 | 2013-09-26 | Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016503070A JP2016503070A (ja) | 2016-02-01 |
| JP2016503070A5 true JP2016503070A5 (zh) | 2016-11-10 |
Family
ID=54250581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551668A Pending JP2016503070A (ja) | 2013-01-04 | 2013-09-26 | 免疫寛容剤と併用してｐｐｉを利用する糖尿病を有する患者の間でのインスリン非依存性 |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP2941250A4 (zh) |
| JP (1) | JP2016503070A (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8732150B2 (en) | 2010-09-23 | 2014-05-20 | Salesforce.Com, Inc. | Methods and apparatus for suppressing network feed activities using an information feed in an on-demand database service environment |
| US9529488B2 (en) | 2013-03-15 | 2016-12-27 | Salesforce.Com, Inc. | Systems and methods for creating custom actions |
| US9665261B2 (en) | 2013-10-28 | 2017-05-30 | Salesforce.Com, Inc. | Providing a user interface for customizing state transitions of panes in a bounding window |
| US10198484B2 (en) | 2015-09-10 | 2019-02-05 | Salesforce.Com, Inc. | Displaying reduced and detailed visual representations of calendar items based on mouse cursor movement |
| JP2019077615A (ja) * | 2016-03-09 | 2019-05-23 | 公立大学法人和歌山県立医科大学 | 非アルコール性脂肪性肝疾患／非アルコール性脂肪性肝炎の治療剤 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2726759C (en) * | 2005-05-25 | 2016-02-16 | Curedm Group Holdings, Llc | Human proislet peptide, derivatives and analogs thereof, and methods of using same |
-
2013
- 2013-09-26 EP EP13840277.1A patent/EP2941250A4/en not_active Withdrawn
- 2013-09-26 JP JP2015551668A patent/JP2016503070A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guggilam et al. | TNF-α blockade decreases oxidative stress in the paraventricular nucleus and attenuates sympathoexcitation in heart failure rats | |
| ES2653615T3 (es) | Pluralidad de dosis de LAG-3 recombinante para su uso en la provocación de una respuesta inmunitaria de monocitos | |
| JP2016503070A5 (zh) | ||
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| JP2020033360A5 (zh) | ||
| JP2012067116A5 (zh) | ||
| Gilday et al. | Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia | |
| Kholdani et al. | Macitentan for the treatment of pulmonary arterial hypertension | |
| KR20210072039A (ko) | 면역절제 요법 | |
| US20230255931A1 (en) | Pharmaceutical compositions useful for the treatment of tissue injury | |
| Lowe et al. | Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy | |
| Edmonds et al. | Influence of commonly used pharmaceutical agents on equine bone marrow‐derived mesenchymal stem cell viability | |
| KR102205368B1 (ko) | Fxr 작용제의 신규 요법 | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| AR068229A1 (es) | Composiciones y metodos para tratar enfermedades y trastornos inmunologicos e inflamatorios | |
| CN105358678A (zh) | 治疗和/或预防1型糖尿病的方法和组合物 | |
| WO2012044783A8 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| JP2016503070A (ja) | 免疫寛容剤と併用してｐｐｉを利用する糖尿病を有する患者の間でのインスリン非依存性 | |
| Ma et al. | Immunosuppressive effect of compound K on islet transplantation in an STZ-induced diabetic mouse model | |
| EP2802342A1 (en) | Peptide and uses thereof | |
| Wu et al. | Steroid-resistant acute rejection after cadaveric liver transplantation: Experience from one single center | |
| Jeon et al. | Rhabdomyolysis associated with single-dose intravenous esomeprazole administration: A case report | |
| Lobritto et al. | Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine | |
| WO2019229525A2 (en) | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRβ ANTIBODY | |
| Colombo et al. | Clinical profile of cyclosporine in dermatology |